$NMLSF News
Last published 4y ago
- 4y agoNMLSFNova Mentis Begins Enrollment in North American Autism StudyPR NewswireVANCOUVER, BC, March 23, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagno
- 4y agoNMLSFNova Mentis Announces Closing of Non-Brokered FinancingPR NewswireVANCOUVER, BC, March 15, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diag
- 4y agoNMLSFNova Mentis Study Confirms Oral Microdose Psilocybin Treatment of AutismPR NewswireVANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagno
- 4y agoKONEFNMLSFWellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership with Nova MentisGlobeNewswireVANCOUVER, British Columbia, Jan. 27, 2022 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited ("Ketamine One" or the "Company") (NEO: MEDI) (OTC:KONEF) (Frankfurt: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artifi
- 4y agoNMLSFNova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical ProgramPR NewswireVANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnos
- 5y agoNMLSFNova Mentis Files Genetic Neuroinflammatory Disease PatentPR NewswireMessenger RNA Diagnostic/Treatment Paradigm VANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocyb
- 5y agoNMLSFU.S. FDA Approves Nova Mentis Orphan Drug ApplicationPR NewswirePsilocybin Fragile X Syndrome Treatment VANCOUVER, BC, Nov. 2, 2021 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin
- 5y agoNMLSFMycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery SystemPR NewswirePartnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders VANCOUVER, BC, Oct. 19, 2021 /PRNewswire/ - October 19, 2021 – Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"